Cargando…
A first-in-human, randomized, controlled, subject- and reviewer-blinded multicenter study of Actamax™ Adhesion Barrier
PURPOSE: Post-surgical adhesions remain a significant concern following abdominopelvic surgery. This study was to assess safety, manageability and explore preliminary efficacy of applying a degradable hydrogel adhesion barrier to areas of surgical trauma following gynecologic laparoscopic abdominope...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5281664/ https://www.ncbi.nlm.nih.gov/pubmed/27844212 http://dx.doi.org/10.1007/s00404-016-4211-x |
_version_ | 1782503181052280832 |
---|---|
author | Trew, Geoffrey H. Pistofidis, George A. Brucker, Sara Y. Krämer, Bernhard Ziegler, Nicole M. Korell, Matthias Ritter, Henning McConnachie, Alex Ford, Ian Crowe, Alison M. Estridge, Trudy D. Diamond, Michael P. De Wilde, Rudy L. |
author_facet | Trew, Geoffrey H. Pistofidis, George A. Brucker, Sara Y. Krämer, Bernhard Ziegler, Nicole M. Korell, Matthias Ritter, Henning McConnachie, Alex Ford, Ian Crowe, Alison M. Estridge, Trudy D. Diamond, Michael P. De Wilde, Rudy L. |
author_sort | Trew, Geoffrey H. |
collection | PubMed |
description | PURPOSE: Post-surgical adhesions remain a significant concern following abdominopelvic surgery. This study was to assess safety, manageability and explore preliminary efficacy of applying a degradable hydrogel adhesion barrier to areas of surgical trauma following gynecologic laparoscopic abdominopelvic surgery. METHODS: This first-in-human, prospective, randomized, multicenter, subject- and reviewer-blinded clinical study was conducted in 78 premenopausal women (18–46 years) wishing to maintain fertility and undergoing gynecologic laparoscopic abdominopelvic surgery with planned clinically indicated second-look laparoscopy (SLL) at 4–12 weeks. The first two patients of each surgeon received hydrogel, up to 30 mL sprayed over all sites of surgical trauma, and were assessed for safety and application only (n = 12). Subsequent subjects (n = 66) were randomized 1:1 to receive either hydrogel (Treatment, n = 35) or not (Control, n = 31); 63 completed the SLL. RESULTS: No adverse event was assessed as serious, or possibly device related. None was severe or fatal. Adverse events were reported for 17 treated subjects (17/47, 36.2%) and 13 Controls (13/31, 41.9%). For 95.7% of treated subjects, surgeons found the device “easy” or “very easy” to use; in 54.5%, some residual material was evident at SLL. For 63 randomized subjects who completed the SLL, adjusted between-group difference in the change from baseline adhesion score demonstrated a 41.4% reduction for Treatment compared with Controls (p = 0.017), with a 49.5% reduction (p = 0.008) among myomectomy subjects (n = 34). CONCLUSION: Spray application of a degradable hydrogel adhesion barrier during gynecologic laparoscopic abdominopelvic surgery was performed easily and safely, without evidence of clinically significant adverse outcomes. Data suggest the hydrogel was effective in reducing postoperative adhesion development, particularly following myomectomy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00404-016-4211-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5281664 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-52816642017-02-13 A first-in-human, randomized, controlled, subject- and reviewer-blinded multicenter study of Actamax™ Adhesion Barrier Trew, Geoffrey H. Pistofidis, George A. Brucker, Sara Y. Krämer, Bernhard Ziegler, Nicole M. Korell, Matthias Ritter, Henning McConnachie, Alex Ford, Ian Crowe, Alison M. Estridge, Trudy D. Diamond, Michael P. De Wilde, Rudy L. Arch Gynecol Obstet General Gynecology PURPOSE: Post-surgical adhesions remain a significant concern following abdominopelvic surgery. This study was to assess safety, manageability and explore preliminary efficacy of applying a degradable hydrogel adhesion barrier to areas of surgical trauma following gynecologic laparoscopic abdominopelvic surgery. METHODS: This first-in-human, prospective, randomized, multicenter, subject- and reviewer-blinded clinical study was conducted in 78 premenopausal women (18–46 years) wishing to maintain fertility and undergoing gynecologic laparoscopic abdominopelvic surgery with planned clinically indicated second-look laparoscopy (SLL) at 4–12 weeks. The first two patients of each surgeon received hydrogel, up to 30 mL sprayed over all sites of surgical trauma, and were assessed for safety and application only (n = 12). Subsequent subjects (n = 66) were randomized 1:1 to receive either hydrogel (Treatment, n = 35) or not (Control, n = 31); 63 completed the SLL. RESULTS: No adverse event was assessed as serious, or possibly device related. None was severe or fatal. Adverse events were reported for 17 treated subjects (17/47, 36.2%) and 13 Controls (13/31, 41.9%). For 95.7% of treated subjects, surgeons found the device “easy” or “very easy” to use; in 54.5%, some residual material was evident at SLL. For 63 randomized subjects who completed the SLL, adjusted between-group difference in the change from baseline adhesion score demonstrated a 41.4% reduction for Treatment compared with Controls (p = 0.017), with a 49.5% reduction (p = 0.008) among myomectomy subjects (n = 34). CONCLUSION: Spray application of a degradable hydrogel adhesion barrier during gynecologic laparoscopic abdominopelvic surgery was performed easily and safely, without evidence of clinically significant adverse outcomes. Data suggest the hydrogel was effective in reducing postoperative adhesion development, particularly following myomectomy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00404-016-4211-x) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2016-11-14 2017 /pmc/articles/PMC5281664/ /pubmed/27844212 http://dx.doi.org/10.1007/s00404-016-4211-x Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | General Gynecology Trew, Geoffrey H. Pistofidis, George A. Brucker, Sara Y. Krämer, Bernhard Ziegler, Nicole M. Korell, Matthias Ritter, Henning McConnachie, Alex Ford, Ian Crowe, Alison M. Estridge, Trudy D. Diamond, Michael P. De Wilde, Rudy L. A first-in-human, randomized, controlled, subject- and reviewer-blinded multicenter study of Actamax™ Adhesion Barrier |
title | A first-in-human, randomized, controlled, subject- and reviewer-blinded multicenter study of Actamax™ Adhesion Barrier |
title_full | A first-in-human, randomized, controlled, subject- and reviewer-blinded multicenter study of Actamax™ Adhesion Barrier |
title_fullStr | A first-in-human, randomized, controlled, subject- and reviewer-blinded multicenter study of Actamax™ Adhesion Barrier |
title_full_unstemmed | A first-in-human, randomized, controlled, subject- and reviewer-blinded multicenter study of Actamax™ Adhesion Barrier |
title_short | A first-in-human, randomized, controlled, subject- and reviewer-blinded multicenter study of Actamax™ Adhesion Barrier |
title_sort | first-in-human, randomized, controlled, subject- and reviewer-blinded multicenter study of actamax™ adhesion barrier |
topic | General Gynecology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5281664/ https://www.ncbi.nlm.nih.gov/pubmed/27844212 http://dx.doi.org/10.1007/s00404-016-4211-x |
work_keys_str_mv | AT trewgeoffreyh afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT pistofidisgeorgea afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT bruckersaray afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT kramerbernhard afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT zieglernicolem afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT korellmatthias afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT ritterhenning afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT mcconnachiealex afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT fordian afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT crowealisonm afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT estridgetrudyd afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT diamondmichaelp afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT dewilderudyl afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT trewgeoffreyh firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT pistofidisgeorgea firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT bruckersaray firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT kramerbernhard firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT zieglernicolem firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT korellmatthias firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT ritterhenning firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT mcconnachiealex firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT fordian firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT crowealisonm firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT estridgetrudyd firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT diamondmichaelp firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier AT dewilderudyl firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier |